A broader horizon of Alzheimer pathogenesis: ALZAS — an early serum biomarker?

  • E. Kienzl
  • K. Jellinger
  • B. Janetzky
  • H. Steindl
  • J. Bergmann
Part of the Journal of Neural Transmission. Supplementa book series (NEURAL SUPPL, volume 62)


Recently, a novel risk gene protein expressed in elderly patientswith the diagnosis of Alzheimer disease (AD) was discovered on chromosome 21 within the APP (amyloid precursor protein) region. This 79 amino acidprotein, ALZAS (Alzheimer Associated Protein) contains the β-amyloid peptide 1–42 fragment, the APP transmembrane signal, and a unique 12 aminoacid c-terminal which is not present in any known allele of the APP gene.Reverse transcription-peR revealed that the transcript of ALZAS was ex-pressed in cortical and hippocampal regions of human Alzheimer diseasebrain as well as in leukocytes derived from AD patients. Most specifically, anendogenous antibody was found in patients with confirmed AD, in patientswith depression, and in subjects suggested to have presymptomatic AD,where it was directed against epitopes within the intron encoded amino acidc-terminal sequence.


Alzheimer Disease Amyloid Precursor Protein Alzheimer Disease Patient Amyloid Beta Protein Alzheimer Disease Brain 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Bullido M, Munoz-Fernandez MA, Recuero M, Fresno M, Valdivieso F (1996)Alzheimer’s amyloid precursor pprotein is expressed on the surface of hematopoieticcells upon activation. Biochim Biophys Acta 1313: 54–62Google Scholar
  2. Butterfield DA, Drake J, Pocernich C, Castegna A (2001) Evidence of oxidative damagein Alzheimer’s disease brain: central role for amyloid ~-peptide. TIMM 7: 548–554Google Scholar
  3. Evenhuis HM (1997) The natural history of dementia in ageing people with intellectualdisability. J Intellect Disabil Res 41: 92–96PubMedCrossRefGoogle Scholar
  4. Geerlings MI, Schoevers RA, Beekman AT, Jonker C, Deeg DJ, Schmand B, Ader HJ,Bouter LM, Van Tilburg W (2000) Depression and risk of cognitive decline andAlzheimer’s disease. Results of two prospective community-based studies in TheNetherlands. Br J Psychiatry 176: 568–75Google Scholar
  5. Ikin A.F., Annaert W.G., Takei K, De Camilli P, Jahn R, Greengard P, Buxbaum J.D (1996)Alzheimer amyloid protein precursor is localizsed in nerve terminal preparations toRab5-containing vesicular organelles distinct from those implicated in the synapticvesicle pathway. J Bioi Chem 271: 31783–31786Google Scholar
  6. Jellinger KA, Rosier N (2000) Neuropathology and biological markers of degenerativedementias. Internist 41: 524–537PubMedCrossRefGoogle Scholar
  7. Kokmen E, Beard C.M., Chandra V., Offord K.P., Schoenberg B.S., Ballard D.J. (1991)Clinical risk factors for Alzheimer’s diseasee: a population-based case-control study.Neurology 41: 1393–1397PubMedCrossRefGoogle Scholar
  8. Koudinov A, Matsubara E, Frangione B, Ghiso J (1994) The soluble form ofAlzheimer’samyloid beta protein is complexed to high density lipoprotein 3 and very high densitylipoprotein in normal human plasma. Biochem Biophys Res Commun 205: 1164–1171PubMedCrossRefGoogle Scholar
  9. Li QX, Fuller StJ. Beyreuther K, Masters CL (1999) The amyloid precursor protein ofAlzheimer disease in human brain and blood. J Leuk Bio 66: 567–574Google Scholar
  10. Lin H, Bhatia R, Lal R (2001) Amyloid beta protein forms ion channels: implications forAlzheimer’s disease pathology. FASEB J 15: 2433–2444PubMedCrossRefGoogle Scholar
  11. McGeer PI, McGeer EG, Yasojima K (2000) Alzheimer disease and neuroinflammation.J Neural Transm [Suppl] 59: 53–57Google Scholar
  12. Mirra SS, Hart MN, Terry RD (1993) Making the diagnosis of Alzheimer’s disease. Aprimer for practicing pathologists.Arch Pathol Lab Med 117: 132–144PubMedGoogle Scholar
  13. Parvathy S., Davies P., Haroutunian V., Purohit DP, Davis K.L., Mohs R.C., Park H,Moran TM,Chan J.Y., Buxbaum J.D. (2001) Correlation between Ax-40-, Ah-42 andA~x,43-containing amyloid plaques and cognitive decline. Arch Neurol58: 2025–3230Google Scholar
  14. Pimplikar S.W.(2002) A~PP, apoptosis and Alzheimer’s disease. J Alzheimer Dis 4: 39–40Google Scholar
  15. Qiu W.Q., Ferreira A, Miller C, Koo EH, Selkoe DJ (1995) Cell-surface~-amyloid precur-sor protein stimulates neurite outgrowth of hippocampal neurons in an isoform-dependent manner. J Neurosci 15: 2157–2167Google Scholar
  16. Rhee SK, Quist AP, Lal R (1998) Amyloid beta protein-(1–42) forms calcium-permeable,Zn2+-sensitive channel. J Bioi Chern 273: 13379–13382CrossRefGoogle Scholar
  17. Saunders AM (2000) Apolipoprotein E and Alzheimer disease: an update on genetic andfunctional analyses. J Neuropathol Exp Neurol59: 751–758Google Scholar
  18. Selkoe DJ (2000) The genetics and molecular pathology of Alzheimer’s disease: roles ofamyloid and the presenilins. Neurol Clin 18: 903–922PubMedCrossRefGoogle Scholar
  19. Selkoe DJ (2001) Clearing the brain’s amyloid cobwebs. Neuron 32(2): 177–180PubMedCrossRefGoogle Scholar
  20. Strohmeyer R, Rogers J (2001) Molecular and cellular mediators of Alzheimer’s diseaseinflammation. J Alzheimer Dis 3: 131–157Google Scholar
  21. The Ronald and Nancy Reagan Research Institute of the Alzheimer’s Association andthe National Institute on Aging Working Group (1998) Consensus report of theWorking Group on “Molecular and biochemical markers of Alzheimer disease”.Neurobiol Aging 19: 109–116Google Scholar
  22. Wilson CA, Doms RW, Lee VM (1999) Intracellular APP processing and A beta produc-tion in Alzheimer disease. J Neuropathol Exp Neurol58: 787–794CrossRefGoogle Scholar
  23. Wisniewski H.M. andWegiel J. (1994) amyloid formation by myocytes ofleptomeningealvessels. Acta Neuropathol 87: 233–241PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Wien 2002

Authors and Affiliations

  • E. Kienzl
    • 1
  • K. Jellinger
    • 1
  • B. Janetzky
    • 2
  • H. Steindl
    • 3
  • J. Bergmann
    • 4
  1. 1.VIENNA HEALTH BOARD and L. B. Institute of Clinical NeurobiologyViennaAustria
  2. 2.Universitätsklinikum Carl Gustav DresdenUniversity of TechnologyDresdenFederal Republic of Germany
  3. 3.Institute of Applied MicrobiologyUniversity of AgricultureViennaAustria
  4. 4.ALTEGEN IncHamburgFederal Republic of Germany

Personalised recommendations